Phenotypic Drug Screening for Dysferlinopathy Using Patient‐Derived Induced Pluripotent Stem Cells
Autor: | Akiko Kume, Tomoko Nagino, Katsunori Sasa, Hidetoshi Sakurai, Katsuya Miyake, Mikiko Fukuda, Ryuichi Tozawa, Tatsuo Oikawa, Yuko Kokubu, Hiromitsu Fuse |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Adult Dysferlinopathy Medicine (General) Drug Evaluation Preclinical Drug target Skeletal muscle Cell‐Based Drug Development Screening and Toxicology Muscle disorder Dysferlin 03 medical and health sciences 0302 clinical medicine R5-920 medicine Myocyte Humans Muscular dystrophy Induced pluripotent stem cell Muscle Cells biology QH573-671 Chemistry Cell Biology General Medicine Middle Aged medicine.disease Cell biology Induced pluripotent stem cells 030104 developmental biology Phenotype Muscular Dystrophies Limb-Girdle Differentiation Proteasome inhibitor biology.protein Female Stem cell Myosin heavy chain Cytology 030217 neurology & neurosurgery Developmental Biology medicine.drug |
Zdroj: | Stem Cells Translational Medicine, Vol 8, Iss 10, Pp 1017-1029 (2019) Stem Cells Translational Medicine |
ISSN: | 2157-6564 2157-6580 |
Popis: | Dysferlinopathy is a progressive muscle disorder that includes limb-girdle muscular dystrophy type 2B and Miyoshi myopathy (MM). It is caused by mutations in the dysferlin (DYSF) gene, whose function is to reseal the muscular membrane. Treatment with proteasome inhibitor MG-132 has been shown to increase misfolded dysferlin in fibroblasts, allowing them to recover their membrane resealing function. Here, we developed a screening system based on myocytes from MM patient-derived induced pluripotent stem cells. According to the screening, nocodazole was found to effectively increase the level of dysferlin in cells, which, in turn, enhanced membrane resealing following injury by laser irradiation. Moreover, the increase was due to microtubule disorganization and involved autophagy rather than the proteasome degradation pathway. These findings suggest that increasing the amount of misfolded dysferlin using small molecules could represent an effective future clinical treatment for dysferlinopathy. Stem Cells Translational Medicine 2019;8:1017–1029 |
Databáze: | OpenAIRE |
Externí odkaz: |